Fujifilm signs influenza drug licensing deal
Japan-based Fujifilm has signed a patent licensing agreement with a Chinese company centring on an ingredient used in its anti-influenza drug Avigan.
The deal, signed with China-based pharmaceutical company Zhejiang Hisun Pharmaceutical yesterday, June 21, gives the Chinese company a licence to develop, manufacture and market anti-influenza drugs in China that contain the favipiravir ingredient.
Fujifilm, better known for photography and imaging but which also makes drugs, will receive a lump-sum payment and royalties once a drug is successfully introduced to the market.
According to Fujifilm, the need to develop new drugs for treating influenza has come after mounting concerns that avian influenza viruses could mutate into a new type of virus capable of human-to-human transmission.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk